RxDoctor Payments Data

Tiffany Jackson

Optometrist · Wilmington, NCNPI 1083837546

Payments from drug & device makers

$1,750in general payments, 2019–2025

Across 33 payments — averaging $53.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$652
  • Bausch & Lomb Americas Inc.$364
  • Biotissue Holdings Inc.$232
  • Rxsight Inc$145
  • AbbVie$141
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$86
  • plus $130 from 3 others

What the payments were for

  • Food & beverage$1,750100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,750 in reported general payments places this provider in the 60th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$97,642
Medicare patients
295
Services billed
1,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost74$29,038
EysuvisLoteprednol Etabonate49$23,726
RocklatanNetarsudil Mesylat/Latanoprost23$10,746
Loteprednol Etabonate30$4,090
CombiganBrimonidine Tartrate/Timolol13$3,408
Prednisolone Acetate93$3,184
SimbrinzaBrinzolamide/Brimonidine Tart11$2,577
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha168$2,082
Travoprost24$1,659
Latanoprost119$1,373
Doxycycline Monohydrate82$995
Timolol Maleate42$522
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat33$499
Dorzolamide Hcl29$448
Cephalexin45$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$141$32,44687 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$86$4,09030 claims
AlconSimbrinza$652$2,57711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →